VJOncology is committed to improving our service to you

ESMO Breast 2020 | CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC

VJOncology is committed to improving our service to you

Sandra Swain

Sandra Swain, MD, FACP, Georgetown University Medical Center, Washington, DC, discusses CLEOPATRA (NCT00567190), a phase III, randomized, double-blind, placebo-controlled study of first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2+ metastatic breast cancer (mBC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter